CareDx (CDNA) reported Q3 2026 revenue of $139M, up 39% YoY, with Testing Services revenue of $119M (+65% YoY) and volume of ~75,900 tests (+51% YoY). GAAP net income was $19M vs $2M a year ago. Adjusted EBITDA rose to $30M from $15M. The company raised full-year 2026 revenue guidance to $520-530M (from $490-500M) and Adjusted EBITDA guidance to $90-100M (from $66-78M). CareDx closed the acquisition of Naveris for $160M cash plus up to $100M contingent consideration. Pipeline advances include AlloHeme and HistoMap Kidney targeting 2027 launches.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
